# A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL

> **NCT02518113** · PHASE1,PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 36 (actual)

## Conditions studied

- T-cell Acute Lymphoblastic Leukemia
- T-cell Lymphoblastic Lymphoma

## Interventions

- **DRUG:** LY3039478
- **DRUG:** Dexamethasone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02518113
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-01
- **Primary completion:** 2018-01-15
- **Final completion:** 2018-01-15
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2019-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02518113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02518113, "A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02518113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*